Cardiology

In the Lab By Sharon Begley

In its first tough test, CRISPR base editing slashes cholesterol levels in monkeys

In the Lab By Elizabeth Cooney

Scientists 3D-map the ‘little brain of the (rat) heart’

Health Tech By Erin Brodwin

Fueled by the Covid-19 pandemic, remote heart monitoring could become tech’s next big target

Pharma By Ed Silverman

Pharmalittle: Hackers linked to Iran sought Gilead Covid-19 data; NIH to test remdesivir with a Lilly drug

In the Lab By Elizabeth Cooney

MIT’s Koch Institute wins STAT Madness with technology to see tiny ovarian tumors

Health By Matthew Herper

New drug from Merck, Bayer reduces hospitalizations for heart failure patients

Health Tech By Rebecca Robbins

The coronavirus is imperiling drug studies. A virtual study of the Apple Watch could be positioned to thrive

Health By Karen Weintraub

Her son died. Two decades later, she met the medical student who got his heart

Pharma By Phil Galewitz — Kaiser Health News

Heart association admits ‘misstep’ in its drug-store aspirin displays with Bayer

Health Tech By Casey Ross

AI has arrived in medical imaging. Now the FDA needs to monitor its impact on patients

Biotech By Matthew Herper

After 21-year journey, Esperion to test market for a cholesterol pill that is less expensive than some competitors

Health By Eric Boodman

How the psychology of a $4.99 price tag might influence who undergoes heart surgery

Health By Matthew Herper

FDA approves AI-based software that helps doctors take ultrasound pictures of the heart

Pharmalot By Ed Silverman

Years later, raw clinical trial data tells us the extent of Avandia’s heart risks

Health By Shraddha Chakradhar

‘Donation after cardiac death’: New heart transplant method being tested for the first time in the U.S.

Biotech By Adam Feuerstein

Regeneron’s Yancopoulos is still bitter over Praluent sales. Can Novartis do better?

Biotech By Matthew Herper

AstraZeneca fish oil drug fails, leaving Amarin as last drug standing

Health Tech By Casey Ross

At Mayo Clinic, AI engineers face an ‘acid test’: Will their algorithms help real patients?

Biotech By Matthew Herper

FDA approves Amarin fish-oil-derived drug to prevent heart attacks and strokes

Biotech By Matthew Herper

With $9.7 billion acquisition, Novartis bets that heart drugs are coming back

Biotech By Chris Morrison

Amarin releases interim EVAPORATE data — and mineral oil makes another appearance

Health By Associated Press

Big study casts doubt on need for many heart procedures

Health By Rebecca Robbins

Apple launches virtual health studies aiming to enroll hundreds of thousands of customers

Biotech By Adam Feuerstein and Matthew Herper

An FDA panel backed Amarin’s fish oil drug. Here’s a detailed breakdown of the debate

Biotech By Matthew Herper and Adam Feuerstein

Most Read

Giving blood thinners to severely ill Covid-19 patients is gaining ground

Blood clots in severe Covid-19 patients leave clinicians with clues about the illness — but no proven treatments

Taking a page from Apple, Fitbit launches a sweeping heart study

‘Where are all our patients?’: Covid phobia is keeping people with serious heart symptoms away from ERs

In fading steel towns, chronically ill patients hope video visits stay after the pandemic goes

Beware the hype over the Apple Watch heart app. The device could do more harm than good

Pharmalittle: Hospitals criticize feds over remdesivir supplies; Moderna starting mid-stage Covid-19 vaccine trials soon

Heart group warns of cardiovascular risks after treatment for breast cancer

All Coverage

In its first tough test, CRISPR base editing slashes cholesterol levels in monkeys

Scientists 3D-map the ‘little brain of the (rat) heart’

Fueled by the Covid-19 pandemic, remote heart monitoring could become tech’s next big target

Pharmalittle: Hackers linked to Iran sought Gilead Covid-19 data; NIH to test remdesivir with a Lilly drug

MIT’s Koch Institute wins STAT Madness with technology to see tiny ovarian tumors

New drug from Merck, Bayer reduces hospitalizations for heart failure patients

The coronavirus is imperiling drug studies. A virtual study of the Apple Watch could be positioned to thrive

Her son died. Two decades later, she met the medical student who got his heart

Heart association admits ‘misstep’ in its drug-store aspirin displays with Bayer

AI has arrived in medical imaging. Now the FDA needs to monitor its impact on patients

After 21-year journey, Esperion to test market for a cholesterol pill that is less expensive than some competitors

How the psychology of a $4.99 price tag might influence who undergoes heart surgery

FDA approves AI-based software that helps doctors take ultrasound pictures of the heart

Years later, raw clinical trial data tells us the extent of Avandia’s heart risks

‘Donation after cardiac death’: New heart transplant method being tested for the first time in the U.S.

Regeneron’s Yancopoulos is still bitter over Praluent sales. Can Novartis do better?

AstraZeneca fish oil drug fails, leaving Amarin as last drug standing

At Mayo Clinic, AI engineers face an ‘acid test’: Will their algorithms help real patients?

FDA approves Amarin fish-oil-derived drug to prevent heart attacks and strokes

With $9.7 billion acquisition, Novartis bets that heart drugs are coming back

Amarin releases interim EVAPORATE data — and mineral oil makes another appearance

Big study casts doubt on need for many heart procedures

Apple launches virtual health studies aiming to enroll hundreds of thousands of customers

An FDA panel backed Amarin’s fish oil drug. Here’s a detailed breakdown of the debate

FDA documents point to a broadened approval for Amarin’s heart pill Vascepa

Most Read

All Coverage